P. Borrego

发表

Rare HIV-1 Subtype J Genomes and a New H/U/CRF02_AG Recombinant Genome Suggests an Ancient Origin of HIV-1 in Angola.

N. Taveira, T. Leitner, Inês Bártolo, 2016, AIDS research and human retroviruses.

Evolutionary and Structural Features of the C2, V3 and C3 Envelope Regions Underlying the Differences in HIV-1 and HIV-2 Biology and Infection

N. Taveira, Inês Bártolo, P. Borrego, 2011, PloS one.

HIV-2 susceptibility to entry inhibitors.

N. Taveira, P. Borrego, 2013, AIDS reviews.

Baseline Susceptibility of Primary HIV-2 to Entry Inhibitors

F. Antunes, N. Taveira, U. Caixas, 2012, Antiviral therapy.

The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients

F. Antunes, N. Taveira, P. Borrego, 2008, Retrovirology.

Epidemic history of hepatitis C virus genotypes and subtypes in Portugal

N. Taveira, R. Marinho, P. Borrego, 2018, Scientific Reports.

HIV-2 Genetic Evolution in Patients with Advanced Disease Is Faster than That in Matched HIV-1 Patients

N. Taveira, T. Leitner, J. Albert, 2010, Journal of Virology.

Title : Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X 4 tropism Running head : Antibody neutralization and escape in HIV-2

F. Antunes, N. Taveira, P. Borrego, 2013 .

Potent and Broadly Reactive HIV-2 Neutralizing Antibodies Elicited by a Vaccinia Virus Vector Prime-C2V3C3 Polypeptide Boost Immunization Strategy

N. Taveira, P. Borrego, A. Quintas, 2010, Journal of Virology.

A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus

N. Taveira, Yuxian He, Xiaohui Ding, 2016, Journal of Virology.

A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies

N. Taveira, L. Graça, Jorge Vítor, 2020, Vaccines.

Evaluation of the fusion inhibitor P3 peptide as a potential microbicide to prevent HIV transmission in women

N. Taveira, M. Bronze, Inês Bártolo, 2018, PloS one.

Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response

N. Taveira, T. Leitner, Inês Bártolo, 2013, Retrovirology.

In vitro evaluation of novel reverse transcriptase inhibitors TAF (tenofovir alafenamide) and OBP-601 (2,3-didehydro-3-deoxy-4-ethynylthymidine) against multi-drug resistant primary isolates of HIV-2.

N. Taveira, U. Caixas, Inês Bártolo, 2019, Antiviral Research.

Long-Term and Low-Level Envelope C2V3 Stimulation by Highly Diverse Virus Isolates Leads to Frequent Development of Broad and Elite Antibody Neutralization in HIV-1-Infected Individuals

N. Taveira, T. Leitner, Inês Bártolo, 2022, Microbiology spectrum.

Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain

N. Taveira, P. Borrego, V. Briz, 2020, Scientific Reports.

Assessment of the Cavidi ExaVir Load Assay for Monitoring Plasma Viral Load in HIV-2-Infected Patients

N. Taveira, I. Barahona, P. Borrego, 2017, Journal of Clinical Microbiology.

Proceedings of the Frontiers of Retrovirology Conference 2016

R. König, D. Elleder, R. Sachidanandam, 2016, Retrovirology.

Epidemic history of hepatitis C virus genotypes and subtypes in Portugal

N. Taveira, R. Marinho, P. Borrego, 2018, Scientific Reports.

High Instantaneous Inhibitory Potential of Bictegravir and the New Spiro-β-Lactam BSS-730A for HIV-2 Isolates from RAL-Naïve and RAL-Failing Patients

N. Taveira, I. Barahona, U. Caixas, 2022, International journal of molecular sciences.

Exclusion Criteria vs Reality: Dual BRAF/MEK Inhibition and Radiotherapy in a Patient with Melanoma Metastatic to the Brain and ECOG 3

Miguel Martín, I. Márquez-Rodas, P. Borrego, 2016, Tumori.

Probing entry inhibitors' activity on HIV and development of new fusion inhibitors : integrating evolutionary biology with virology

P. Borrego, 2011 .

Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism

F. Antunes, N. Taveira, P. Borrego, 2012, AIDS.

Envelope-specific antibody response in HIV-2 infection: C2V3C3-specific IgG response is associated with disease progression

F. Antunes, N. Taveira, P. Borrego, 2008, AIDS.

Origin and Epidemiological History of HIV-1 CRF14_BG

N. Taveira, F. McCutchan, R. Camacho, 2011, PloS one.

Development of water-soluble polyanionic carbosilane dendrimers as novel and highly potent topical anti-HIV-2 microbicides.

N. Taveira, B. Rodés, R. Gómez, 2015, Nanoscale.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

A genotypic method for determining HIV-2 coreceptor usage enables epidemiological studies and clinical decision support

Joachim Büch, Thomas Lengauer, Rolf Kaiser, 2016, Retrovirology.

An ancestral HIV-2/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activity

N. Taveira, R. Calado, P. Borrego, 2013, AIDS.

Genetic diversity and drug resistance profiles in HIV type 1- and HIV type 2-infected patients from Cape Verde Islands.

F. Antunes, N. Taveira, V. Oliveira, 2011, AIDS research and human retroviruses.

Potency of HIV-2-specific antibodies increase in direct association with loss of memory B cells

N. Taveira, R. Calado, P. Borrego, 2017, AIDS.

An HIV-1/HIV-2 Chimeric Envelope Glycoprotein Generates Binding and Neutralising Antibodies against HIV-1 and HIV-2 Isolates

N. Taveira, Inês Bártolo, R. Calado, 2023, International journal of molecular sciences.

A genotypic method for determining HIV-2 coreceptor usage enables epidemiological studies and clinical decision support

Thomas Lengauer, N. Taveira, R. Kaiser, 2016, Retrovirology.

Antagonism of BST-2/Tetherin Is a Conserved Function of the Env Glycoprotein of Primary HIV-2 Isolates

N. Taveira, Chia-yen Chen, K. Strebel, 2016, Journal of Virology.

Development of synthetic light-chain antibodies as novel and potent HIV fusion inhibitors

N. Taveira, M. Castanho, F. Aires-da-Silva, 2016, AIDS.

Genotypic resistance profiles of HIV-2 infected patients from Cape Verde failing first-line antiretroviral therapy.

N. Taveira, P. Borrego, P. Gómes, 2019, AIDS.